Skip to Main Content

Two patients with cancer showed partial tumor shrinkage after infusions of a novel immune-boosting treatment derived from red blood cells, its maker Rubius Therapeutics said Monday.

Rubius said the preliminary results of its early-stage clinical trial provided “clinical validation” of its treatment, called RTX-240. However, the company was unable to show data proving RTX-240 triggered the expected immune system attack against the patients’ tumors, leaving questions about its future unanswered. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED